From StockNews.com: Bristol-Myers Squibb Co (NYSE:BMY) early Thursday posted mixed fourth quarter earnins reuslts and lowered its 2017 outlook, amid fears of regulators capping drug prices.

The New York City-based pharmaceuticals giant reported Q4 EPS of $0.63, which was $0.03 worse than the Wall Street consensus estimate of $0.66. Revenues surged 22.3% from last year to $5.24 billion, however, beating analysts’ $5.13 billion view. BMY also noted that international revenues increased an even better 25%, or 28% when excluding currency exchange effects.

Bristol-Myers’ gross margin as a percentage of revenue fell to 73.6% in the latest period, down from 77.8%, hurt by an unfavorable product mix.

BMY provided the following global revenue results for its drugs in Q4:

• Opdivo grew by $835 million
• Eliquis grew by $346 million (up 57%)
• Orencia grew 16%
• Sprycel grew 15%
• Yervoy had sales of $264 million

Looking ahead, BMY cut its earnings guidance for 2017. It now expects EPS for the year of $2.70 to $2.90, which is lower than Wall Street’s $2.97 estimate. Worldwide revenues are now seen rising in the low-single digits (previously, BMY expected a high-teens increase), and gross margin as a percentage of revenue is now expected to range from 72% to 73% (down from a prior 75%).

Bristol-Myers Squibb Co shares fell $1.05 (-2.12%) in premarket trading Thursday. Prior to today’s report, BMY had declined -14.65% year-to-date, versus a 2.70% rise in the benchmark S&P 500 index during the same period.

BMY currently has a StockNews.com POWR Rating of D (Sell), and is ranked #53 of 133 stocks in the Medical – Pharmaceuticals category.

This article is brought to you courtesy of StockNews.com.

You are viewing an abbreviated republication of ETF Daily News content. You can find full ETF Daily News articles on (www.etfdailynews.com)

Powered by WPeMatico